🇺🇸 FDA
Pipeline program

REGN1908

R1908-1909-ALG-2416

Phase 3 small_molecule completed

Quick answer

REGN1908 for Allergic Conjunctivitis is a Phase 3 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Regeneron UK Limited
Indication
Allergic Conjunctivitis
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials